hydroxycamptothecin
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
1
Phase 4
0
Earliest trial started Mar 1, 2014 (NCT02755311)
Timeline
2010s
- Jan 1, 2014
Earliest Phase 3 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Topoisomerase I/IIINHIBITOR
Topoisomerase I/II inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3cc(O)ccc3nc2-1- Mol. weight
- 364.36 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL273862 ↗
Also known as
- hydroxycamptothecin
- hydroxycamptothecin
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02755311 | Phase 3 | Mar 1, 2014 | Sun Yat-Sen University |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Sun Yat-Sen University | Academic/Hospital | 1 | 1 | 1 | 2014 |
1 organizations
Page 1 / 1